In conclusion, despite a lower seroprevalence and humoral response to the SARS-CoV-2 vaccine in patients treated with anti-TNF, cellular response to the vaccine did not significantly differ in patients treated with biologic drugs compared with patients who did not receive IBD therapy. The gene discussed is TNF; the disease is inflammatory bowel disease.